Takeda Pharmaceutica

4502

End-of-day quote Tokyo - 02/19

4500JPY

-0.18%

	Actuals in M JPY	Estimates in M JPY
Fiscal Period March	2018	2019
Sales	1 770 531	2 463 170
EBITDA	437 460	538 767
Operating profit (EBIT)	-	-
Pre-Tax Profit (EBT)	217 205	221 296
Net income	186 886	179 678
EPS ( JPY )	239	134
Dividend per Share ( JPY )	180	180
Yield	3,47%	3,99%
Announcement Date	05/14/2018 06:00am	-

	Actuals in M JPY	Estimates in M JPY
Fiscal Period March	2018	2019
Debt	610 494	5 789 399
Finance	-	-
Operating income (EBITDA)	437 460	538 767
Leverage (Debt/EBITDA)	1,40x	10,7x
Capital Expenditure	67 005	142 914
Book Value Per Share (BVPS)	2 557 JPY	3 736 JPY
Cash Flow per Share	490 JPY	314 JPY
Announcement Date	05/14/2018 06:00am	-

Size	2019e	2020e
Capitalization	7 055 042 M JPY	-
Entreprise Value (EV)	12 844 441 M JPY	12 390 817 M JPY

Valuation	2019e	2020e
P/E ratio (Price / EPS)	33,6x
Capitalization / Revenue	2,86x	2,01x
EV / Revenue	5,21x	3,53x
EV / EBITDA	23,8x	12,6x
Yield (DPS / Price)	3,99%	3,99%
Price to book (Price / BVPS)	1,21x	1,42x

Profitability	2019e	2020e
Operating Margin (EBIT / Sales)	-	-
operating Leverage (Delta EBIT / Delta Sales)	-	-
Net Margin (Net Profit / Revenue)	7,29%	1,60%
ROA (Net Profit / Asset)	1,96%	2,90%
ROE (Net Profit / Equities)	4,02%	4,28%
Rate of Dividend	134%	-54 579%

Balance Sheet Analysis	2019e	2020e
CAPEX / CA	5,80%	5,94%
Cash Flow / Sales	19,8%	25,8%
Capital Intensity (Assets / Sales)	3,72x	0,55x
Financial Leverage (Net Debt / EBITDA)	10,7x	5,44x